Editorial: Emerging evidence for critical involvement of the interleukin-17 pathway in both psoriasis and psoriatic arthritis

Arthritis and Rheumatology

Volumn 66, Issue 5, 2014, Pages 1077-1080

  Fitzgerald, Oliver ^a   Winchester, Robert ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN; CD8 ANTIGEN; EPITOPE; INTERLEUKIN 17; INTERLEUKIN 17F; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; USTEKINUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ALLELE; ANTIGEN PRESENTATION; BONE DESTRUCTION; BONE REMODELING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR IMMUNITY; CHROMOSOME 1; CHROMOSOME 6; CLINICAL FEATURE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DOWN REGULATION; EDITORIAL; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENOTYPE; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; OSSIFICATION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVITIS; T CELL DEPLETION; TH17 CELL;

ARTHRITIS, PSORIATIC; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-17; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84899748064     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38370     Document Type: Editorial

References (19)

1. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014; 66: 1272-81.
2. Miossec P,. IL-17 and Th17 cells in rheumatoid arthritis and other inflammatory conditions. In: Th 17 cells: role in inflammation and autoimmune disease., Quesniaux V, Ryffel B, Padova FD, editors. London: Springer; 2009. p. 233-42.
3. Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg DA, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012; 64: 1134-44.
4. Eder L, Chandran V, Pellet F, Shanmugarajah S, Rosen CF, Bull SB, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 2012; 71: 50-5.
5. Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT,. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-91.
6. Costello P, Bresnihan B, O'Farrelly C, FitzGerald O,. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999; 26: 1117-24.
7. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166: 2878-86.
8. Curran SA, FitzGerald OM, Costello PJ, Selby JM, Kane DJ, Bresnihan B, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004; 172: 1935-44.
9. Winchester R, Itescu S,. HIV and the rheumatic diseases. In:, Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. 1st ed. Oxford: Oxford University Press; 1993. p. 560-73.
10. Haroon M, Giles JT, Winchester R, FitzGerald OM,. Role of particular class I MHC haplotypes in determining different traits within the psoriatic arthritis phenotypes [abstract]. Arthritis Rheum 2012; 64 Suppl: S434.
11. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
12. Bowes J, Barton A,. The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med 2010; 10: 177-83.
13. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010; 42: 996-9.
14. Doyle MS, Collins ES, Fitzgerald OM, Pennington SR,. New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis. Arthritis Res Ther 2012; 14: 226.
15. Kirkham BW, Kavanaugh A, Reich K,. Interleukin-17A. A unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis, and rheumatoid arthritis. Immunology 2014; 141: 133-42.
16. - entheseal resident T cells. Nat Med 2012; 18: 1069-76.
17. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al, for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) [published erratum appears in Lancet 2008;371:1838]. Lancet 2008; 371: 1665-74.
18. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al, on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
19. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73: 349-56.